Cambridge, MA – GC Therapeutics has announced the appointment of Stefan Irion as Chief Scientific Officer. About GC Therapeutics: GC Therapeutics (GCTx) is a pioneering biopharmaceutical company harnessing the worlds first plug-and-play induced pluripotent stem cell (iPSC) cellular programming platform, TFome, to revolutionize cell therapy by overcoming development and scaling complexities. TFome integrates advancements in synthetic biology, gene editing, cell engineering, and machine learning to deliver off-the-shelf iPSC-based medicines up to 100 times more rapidly than conventional methods, with improved potency, efficiency, quality, and cost through a single-step process yielding SuperCells. The company is advancing a pipeline of potential best-in-class cell therapy programs focused on gastrointestinal, neurological, and immunological diseases to enhance patient access across diverse therapeutic areas. Co-founded by Parastoo Khoshakhlagh, Ph.D., Alex Ng, Ph.D., Cory Smith, Ph.D., and George Church, Ph.D., GCTx originated from technology developed in Professor George Church’s lab at Harvard Medical School and the Wyss Institute. Founded in 2019 and based in Cambridge, MA, GCTx has raised $75 million from leading life sciences investors including Cormorant Asset Management, Mubadala Capital, a16z Bio + Health, and Medical Excellence Capital.

For more information visit: https://www.gc-tx.com/

GC Therapeutics
610 Main Street
Cambridge, MA 2139
Phone:
LinkedIn Page: https://www.linkedin.com/company/gctx/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved